vTv Therapeutics News

Express News | VTv Therapeutics Inc - Net Loss Attributable to vTv Shareholders for Three Months Ended March 31, 2024, Was $4.9 Mln or $1.17 per Basic Share

ReutersMay 9 17:16 ET

Express News | VTv Therapeutics Q1 Operating Expenses USD 6.627 Million

ReutersMay 9 16:51 ET

Express News | VTv Therapeutics Q1 Operating Income USD -5.627 Million

ReutersMay 9 16:51 ET

vTv Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 16:42 ET · Announcements

Express News | VTv Therapeutics Inc - Qtrly Revenue $1 Mln

ReutersMay 9 16:31 ET

Express News | VTv Therapeutics Inc - Qtrly Net Loss Attributable $1.17 per Basic Share

ReutersMay 9 16:30 ET

VTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

PDF Version HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy

vTv TherapeuticsMay 9 00:00 ET

VTv Therapeutics Files $250M Mixed Securities Shelf

Seeking AlphaApr 10 17:19 ET

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

PR NewswireMar 19 08:30 ET

VTv Therapeutics Appoints Anne Phillips, Reshuffles Board Committees

TipRanksMar 14 08:12 ET

Express News | VTv Therapeutics Q4 EPS $(1.67) Up From $(2.28) YoY

Moomoo 24/7Mar 13 08:03 ET

Press Release: VTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update -- Recently completed $51 million PIPE from healthcare-focused institutional inve

Dow JonesMar 13 08:00 ET

VTv Therapeutics 4Q Loss/Shr $1.67 >VTVT

VTv Therapeutics 4Q Loss/Shr $1.67 >VTVT

Dow JonesMar 13 08:00 ET

VTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

PDF Version Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund. Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adju

vTv TherapeuticsMar 13 00:00 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersNKGen Biotech (NASDAQ:NKGN) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap stands at $30.6 million. vTv Therapeutics (NASDAQ:VTVT) stock moved

BenzingaMar 5 16:31 ET

VTv Therapeutics Enhances Investor Communication With Update

TipRanksMar 5 08:23 ET

Express News | VTv Therapeutics Announces FDA Submission For Phase 3 Study Of Cadisegliatin In Patients With Type 1 Diabetes

Moomoo 24/7Mar 4 08:04 ET

VTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients With Type 1 Diabetes

PDF Version HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP3

vTv TherapeuticsMar 4 00:00 ET

VTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

PDF Version HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP3

vTv TherapeuticsMar 1 00:00 ET

Top Midday Gainers

Vivani Medical's (VANI) shares quadrupled after the company announced positive preclinical data on its NPM-115 implant for weight loss, comparable to Novo Nordisk's Ozempic and Wegovy. More than 126.8

MT NewswiresFeb 28 14:22 ET